Since INSYS Therapeutics Inc. (NASDAQ:INSY) and Puma Biotechnology Inc. (NASDAQ:PBYI) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation of both companies.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INSYS Therapeutics Inc.	82.08M	4.23	124.51M	-1.60	0.00
Puma Biotechnology Inc.	250.99M	5.41	113.58M	-3.90	0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of INSYS Therapeutics Inc. and Puma Biotechnology Inc.

Profitability

Table 2 shows us the return on equity, return on assets and net margins of both companies.

	Net Margins	Return on Equity	Return on Assets
INSYS Therapeutics Inc.	-151.69%	-362%	-50.8%
Puma Biotechnology Inc.	-45.25%	-430.7%	-105.8%

Volatility and Risk

INSYS Therapeutics Inc.’s current beta is 2.56 and it happens to be 156.00% more volatile than S&P 500. Puma Biotechnology Inc.’s 0.64 beta is the reason why it is 36.00% less volatile than S&P 500.

Liquidity

INSYS Therapeutics Inc.’s Current Ratio and Quick Ratio are 0.7 and 0.6 respectively. The Current Ratio and Quick Ratio of its competitor Puma Biotechnology Inc. are 3 and 3 respectively. Puma Biotechnology Inc. therefore has a better chance of paying off short and long-term obligations compared to INSYS Therapeutics Inc.

Analyst Ratings

INSYS Therapeutics Inc. and Puma Biotechnology Inc. Ratings and Recommendations are available on the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
INSYS Therapeutics Inc.	1	0	3	2.75
Puma Biotechnology Inc.	0	0	0	0.00

The consensus price target of INSYS Therapeutics Inc. is $7.75, with potential upside of 65.95%.

Insider & Institutional Ownership

Institutional investors held 18.9% of INSYS Therapeutics Inc. shares and 94.9% of Puma Biotechnology Inc. shares. Insiders held 63.83% of INSYS Therapeutics Inc. shares. Comparatively, Puma Biotechnology Inc. has 11.3% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
INSYS Therapeutics Inc.	0.95%	83.82%	2.42%	-20.1%	-13%	81.71%
Puma Biotechnology Inc.	40.09%	43.76%	74.41%	-3.88%	-35.09%	96.95%

For the past year INSYS Therapeutics Inc. has weaker performance than Puma Biotechnology Inc.

Summary

Puma Biotechnology Inc. beats on 7 of the 11 factors INSYS Therapeutics Inc.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. Its lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.